Adverse effect · Pramlintide

How common is adverse effects with Pramlintide?

A
Grade A — established in humansSame trials · effect size: moderate · adverse
Short answerEstablished in humans. Same trials point the same way: a moderate effect. Nausea in a large minority early on, fading with time; and, when combined with insulin, a risk of severe hypoglycaemia that carries a boxed warning in the US label.

What the studies show

Nausea in a large minority early on, fading with time; and, when combined with insulin, a risk of severe hypoglycaemia that carries a boxed warning in the US label.

“Nausea, the most common adverse event with pramlintide in the 4-month study (9-29% pramlintide vs. 2% placebo), was generally mild to moderate and occurred in <10% of subjects during the extension.”

Verbatim, from the abstractSmith SR, Aronne LJ, Burns CM, et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care, 2008

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
  2. 2
    Pramlintide acetate (Symlin) prescribing information.FDALicensed indications, glucose and weight data, boxed warning.

In context

Pramlintide is a synthetic analogue of amylin, the hormone the pancreas releases with insulin to slow digestion and signal fullness. It is approved in the United States — and nowhere else — as an injection taken with meals alongside insulin in type 1 and type 2 diabetes. In people with obesity but no diabetes, a 12-month trial produced about 6–7 kg of placebo-corrected weight loss at the best doses, with nausea in up to a third at the start. It was never a commercial success, but its mechanism is the one cagrilintide and amycretin have since made weekly.

Pramlintide is approved (rx, us only). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Pramlintide proven to cause adverse effects?
Yes, as far as human trials can show it: Same trials. LYO grades this outcome A.
What studies are behind the grade?
Nausea in a large minority early on, fading with time; and, when combined with insulin, a risk of severe hypoglycaemia that carries a boxed warning in the US label.
Is Pramlintide approved for this?
Pramlintide is an approved medicine (Approved (Rx, US only)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Pramlintide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 10 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →